key: cord-0841252-oatwfawm
authors: Yonezawa, Sei; Koide, Hiroyuki; Asai, Tomohiro
title: Recent advances in siRNA delivery mediated by lipid-based nanoparticles
date: 2020-08-06
journal: Adv Drug Deliv Rev
DOI: 10.1016/j.addr.2020.07.022
sha: 97bc4a9a53cfbaa2f89fc0fb1ddeea5c17e22588
doc_id: 841252
cord_uid: oatwfawm

Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the treatment of broad-spectrum intractable diseases. However, its unfavorable properties such as easy degradation in the blood and negative-charge density are still a formidable barrier for clinical use. For disruption of this barrier, siRNA delivery technology has been significantly advanced in the past two decades. The approval of Patisiran (ONPATTRO™) for the treatment of transthyretin-mediated amyloidosis, the first approved siRNA drug, is a most important milestone. Since lipid-based nanoparticles (LNPs) are used in Patisiran, LNP-based siRNA delivery is now of significant interest for the development of the next siRNA formulation. In this review, we describe the design of LNPs for the improvement of siRNA properties, bioavailability, and pharmacokinetics. Recently, a number of siRNA-encapsulated LNPs were reported for the treatment of intractable diseases such as cancer, viral infection, inflammatory neurological disorder, and genetic diseases. We believe that these contributions address and will promote the development of an effective LNP-based siRNA delivery system and siRNA formulation.

Oligonucleotides such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are ideal drug candidates that are able to be chemically synthesized and directly act on a target gene in a sequence-dependent manner [1, 2] . They are expected as a promising drug modality to fulfill unmet medical needs that have not been satisfied with the use of small molecule-or antibody-based drugs. Because gene silencing with siRNA is triggered by a RNA-induced silencing complex (RISC) system [3] , an endogenous enzyme system, siRNA is capable of targeting all genes in principle. The expression of splicing variants and mutants can be also inhibited by RNA interference (RNAi), suggesting that siRNA is applicable for targeting undruggable proteins. Thus, the for the treatment of TTR-type familial amyloid polyneuropathy. Systemic administration of LNPs loaded with siRNA targeting TTR suppresses the deposition of amyloid fibrils of misfolded TTR in the peripheral nerves and heart [21, 22] . The LNP is the most successful platform for siRNA delivery in the clinical setting and is expected to be applied for the treatment of various diseases. [25] . This study also demonstrated that the incorporation of an been significantly advanced [29, 30] . One of the methods for LNP preparation involves microfluidic mixing of a lipid mixture in ethanol and siRNA in citrate buffer (pH 4.0) followed by dialysis in phosphate buffer to remove the ethanol [31] . The microfluidic mixing method enables the control of particle size and affords high siRNA encapsulation efficiency (~ 100%) and mass production. The structure of LNPs prepared by the microfluidic mixing method has been determined by molecular modeling [32] . The results showed that LNPs have a predominantly hydrophobic core consisting of reverse micelles of DLin-KC2-DMA that have interacted with siRNA, phospholipid, and cholesterol, with the surface of the lipid bilayer coated with PEG. Recent structural studies on LNPs performed by the use of cryo-transmission electron microscopy (TEM) and small-angle X-ray approaches showed that the siRNA/DLin-KC2-DMA complex is present in the form of a sandwich of siRNA in the lipid bilayer at pH 4.0 but that the ionizable lipids in the bilayer structure form an amorphous oil phase in the center of the LNP as the pH is brought closer to neutral [33, 34] .

In order to develop siRNA-encapsulated nanoparticles with several functions to overcome multi-step barriers in the body, it is essential to mount functional molecules in one nano-particle for carrying out each function. For this purpose, Harashima et al. proposed the concept of a multi-functional envelope-type nano device (MEND) for nucleic acid delivery [35] . As shown in Fig. 4a , this particle has a structure in which siRNA is encapsulated in the inner phase of a lipid bilayer modified with functional molecules such as peptides. For example, octaarginine-modified MEND has been reported to be taken up into cells by macropinocytosis followed by the efficient release of the nucleic acids into the cytoplasm [36] . Intracellular dynamics can be controlled by introducing fusible or pH-responsive lipids into the lipid membranes. Harashima's group has been working to develop their own pH-responsive ionizable lipids, resulting in the first-generation YSK05 [37] , second-generation YSK13 [38] , and third-generation CL4H6 (Fig. 4b ) [39] . YSK05, an ionizable lipid designed based on the structure of DODAP, has a tertiary amine and unsaturated fatty acid chains and a pKa of 6.4, which lipid enhances the transfection efficiency by promoting endosomal escape. It has been shown that YSK05-MEND exhibits high membrane fusion and gene knockdown activity [37] . Next, YSK13 was developed to enhance the gene-silencing efficiency of MEND [38] . It was revealed that the ED 50 (0.015 mg/kg) of blood-clotting factor VII (FVII) knockdown in mice intravenously injected with YSK13-MEND with a pKa of 6.45 was more than 4 times less than that of YSK05-MEND [38] . CL4H6 with a pKa of 6.25 was developed by a systematic study on the structure of the ionizable lipid [39] . It was shown that the structure of the head group of ionizable lipids is a primary key to determine the pKa and is important for liver distribution and endosomal J o u r n a l P r e -p r o o f escape of LNPs. It was also reported that the structure of the hydrophobic tail does not affect the apparent pKa. This systematic study revealed how the structure of the head group of ionizable lipids affects the carrier's characteristics. In addition, the ED 50 of Factor VII knockdown after the intravenous injection of CL4H6 LNPs into mice was shown to be 0.0025 mg/kg [39] , indicating that gene-silencing efficiency of LNPs is considerably improved by the systematic study on the structure of the ionizable lipid.

Akita et al. developed SS-cleavable and pH-activated lipid-like material (ssPalm) as a component of LNPs encapsulating nucleic acids [40] [41] [42] . LNPs containing ssPalm (ssPalm-LNPs) are neutral in charge at physiological pH. It has been shown that after internalization of ssPalm-LNPs into cells via endocytosis, ssPalm-LNPs destabilize the endosomal membrane under the acidic condition of the endosome and disintegrate under the reducing environment in the cytoplasm. ssPalm is a lipid derivative that has two tertiary ssPalmM-LNPs showed efficient endosomal escape and biodegradability, indicating them to be useful for delivering nucleic acids and controlling particle fate [40] . ssPalmA (Fig. 5b) and ssPalmE (Fig. 5c) , which contain vitamin A and E as hydrophobic chains of ssPalm, respectively, have been developed for nucleic acid delivery as the second generation of ssPalm. Since vitamin A in ssPalmA makes it possible to utilize the nuclear transport system operated by cellular retinoic acid-binding protein, the gene-transfer efficiency of ssPalmA-LNPs was dramatically increased compared with that for ssPalm-LNPs [43] .

ssPalmE LNPs are a potential gene carrier with anticancer activity derived from α-tocopherol [44] . In siRNA delivery, intravenously administered ssPalmE-LNP, which uses vitamin E as a hydrophobic scaffold, knocked down FVII more efficiently than ssPalmM or ssPalmA [41] . Furthermore, an improved ssPalmE has been developed in which the tertiary amine of ssPalmE is fixed to the piperidine structure to increase the distance between the surface of the particle and the tertiary amine. The FVII knockdown effect of the improved ssPalm E-LNP achieved an ED 50 of 0.035 mg/kg.

On the other hand, activated hepatic stellate cells, which have the ability to produce extracellular matrix, are thought to promote hepatic fibrosis and liver cirrhosis [45] .

These cells are known to store vitamin A intracellularly in order to maintain homeostasis [46] .

Comparing the type I collagen a-1 knockdown effect of 3 kinds of ssPalm-LNPs, J o u r n a l P r e -p r o o f Journal Pre-proof ssPalmA-LNP showed the highest inhibitory effect on hepatic fibrosis, with an ED 50 of 0.25 mg/kg [47] .

Nanoparticles (NPs) composed of lipid-like materials, termed "lipidoids," have also been studied for siRNA delivery [48] . The structures of some such lipidoids are shown in Figure 6 . The advantages of lipidoids are that their structure can be freely arranged to improve in vivo kinetics, efficacy, and safety of lipidoid NPs. The effect of differences in the partial structure of lipidoids on the properties of lipidoid NPs can be analyzed in the process of screening lipidoids, which enable to predict their potential from the structure and reduce the number of experiments.

There have been three screening research reports on lipidoid NPs from Anderson's group over the last decade [49] [50] [51] . The ED 50 [52, 53] . However, the precise delivery mechanism has not been fully elucidated.

In recent years, siRNA delivery with lipidoid NPs has been reported for the treatment of inflammation [54] and intestinal disease by oral administration [55] . These studies will provide new insights into siRNA delivery to various target tissues other than the liver.

be applied to the control of sustained siRNA release.

Exosomes, endogenous vesicles carrying nucleic acids and proteins, have been received a lot of attention in the field of siRNA delivery research, and are expected to be a safe and efficient DDS carrier [69, 70] . It has been clarified that tissues in which exosomes accumulate differ depending on the cells that produce exosomes [71] . It has also been reported that the surface molecules expressed on exosomes are different depending on the type and state of the exosome-producing cells [72, 73] . When exosomes are used as an siRNA carrier, the exosome-producing cells are preferably cells derived from self-tissues in consideration of safety and immunogenicity. Although the use of exosomes as an siRNA carrier is still highly experimental, it has been reported that exosomes collected from human serum can be encapsulated with siRNA by electroporation and introduced into human monocytes and lymphocytes [74, 75] . Exosomes produced by the recipients' own cells will be a potential carrier for siRNA delivery.

The surface of exosomes can be modified with ligand molecules to increase selectivity for target cells. Alvarez-Erviti et al. established dendritic cells that produce exosomes constitutively expressing rabies viral glycoprotein (RVG) peptide for selectively targeting neuronal cells [76] . In order to display the RVG peptide on the exosome surface, can cross the blood-brain barrier (BBB) and deliver siRNA into neuronal cells.

ExoCarta (www.exocarta.org), an exosome database, contains information on constituent molecules of exosomes, including proteins, mRNAs, miRNAs, and lipids [77] .

From the findings of exosome studies, it is expected to construct artificial exosomes or exosome mimetics useful for tissue-specific delivery of siRNA.

3 Strategy to achieve efficient siRNA delivery 3.1 Improvement of siRNA properties by chemical modification Chemical modification of siRNA can suppress off-target effects and improve gene silencing efficiency, although too much modification may interfere with RISC formation [78] .

The position and frequency of chemical modification should be appropriate to use siRNA for therapeutic applications without off-target effects [79] . Appropriate triazole modification of J o u r n a l P r e -p r o o f the guide strand of siRNA has been reported to suppress off-target effects induced by the guide strand, increase the stability of siRNA, and attenuate unfavorable immune stimulation [79] [80] [81] [82] . The effect of nucleotide analogues at the 3′-overhang on gene silencing has been clarified to design the sequence of siRNA [83] . In addition, innate immune responses can be prevented by use of 2'OMe-modified siRNA which is used in Patisiran. Thus, chemical modification of siRNA is important for the development of siRNA-encapsulated LNP formulations.

Another interesting siRNA chemical modification is the preparation of lipid-siRNA conjugates such as those with cholesterol [84] . It has been reported that such modification not only results in exonuclease resistance but also promotes cellular uptake and increases the blood retention time by binding to LDL and high-density lipoproteins (HDL). Conjugates of N-acetyl-D-galactosamine (GalNAc) and siRNA have been used for in vivo targeting to hepatocytes [85] . GalNAc conjugated with siRNA binds to the asialoglycoprotein receptor on hepatocytes and can reduce the distribution of siRNA to peripheral tissues. The conjugation

The cell membrane is a barrier to be overcome for efficient delivery of siRNA.

Cellular uptake and endocytosis pathway of LNP are determinants for delivery of siRNA into cytoplasm. Conjugation of siRNA or LNP with cell-penetrating peptide (CPP), antibody or other ligands improves the cellular uptake of siRNA [87] [88] [89] [90] . Enhancement of membrane fusion with LNP by use of DOPE or fusogenic peptides also improves the cellular uptake of siRNA [37, 91] .

MEND modified with two kinds of CPP peptides, octaarginine (R8) and GALA, has been shown to be a potential carrier for siRNA delivery into dendritic cells [92] . It was shown that that MEND modified with R8 is effectively internalized into cells via macropinocytosis [93] . Modification of MEND with GALA which adopts a random coil structure in physiological pH and an α-helix structure in acidic pH [94] was shown to facilitate endosomal escape [37, 95] . Therefore, MEND modified with R8 and GALA can overcome multiple barriers, resulting in efficient delivery of siRNA into dendritic cells.

Ligand-mediated targeting of LNP to surface receptors on cancer cells has been achieved for siRNA delivery by use of transferrin [96, 97] , folic acid [98] or antibodies [99, 100] . Internalizing receptors suitable for cellular uptake enhancement of LNP have been J o u r n a l P r e -p r o o f identified in various tissues [101] [102] [103] . We previously developed LNP decorated with an Fab' antibody against heparin-binding epidermal growth factor-like growth factor (HB-EGF)

for siRNA delivery to triple-negative breast cancer cells overexpressing HB-EGF on their cell surface. [99, 104] . Decoration with anti-HB-EGF Fab' antibody significantly increased the association and internalization of LNP encapsulating siRNA. Intravenous injection of siRNA targeting polo-like kinase 1 (PLK1) with this formulation significantly suppressed the growth of MDA-MB-231 human triple-negative tumors in mice. These findings support that enhancement of cellular uptake of LNP by ligand-mediated targeting is highly effective for delivery of siRNA.

Intracellular dynamics of LNPs is one of great concern to improve the efficiency of siRNA delivery. When LNPs that encapsulate siRNA are taken up into cells by endocytosis, they are sent to late endosomes followed by lysosomes and then degraded [105] . For this reason, LNPs should have a function for endosomal escape and for release of the siRNA into the cytoplasm [24] . The pKa of the ionizable lipid is an important parameter that strongly affects the efficiency of siRNA delivery [26] . The optimal pKa range for gene silencing in hepatocytes has been shown to be 6.2-6.5, suggesting that cationization of ionizable lipids [25, 26, 31] . The design of an appropriate formulation of LNPs must be required to capture siRNA in LNPs and induce efficient endosomal escape of LNPs [109] .

The control of siRNA kinetics after internalization of LNPs into cells is critical for siRNA delivery. It has been reported that only a small amount of the siRNA internalized into cells contributes to gene silencing, as most of the siRNA internalized is released to the outside of cells by endocytic recycling [105] .

The Niemann-Pick type C-1 protein (NPC-1), a lysosomal membrane protein that mediates intracellular cholesterol transport, is considered to play an important role in the regulation of major recycling pathways of siRNA. In NPC-1 knockout cells, the extracellular recycling pathway of siRNA transfection with LNPs is inhibited, resulting in an increased intracellular concentration of siRNA and enhanced gene-silencing efficiency [110] . These LNPs increases [31] . Increased PEG density on the surface of LNPs has been shown to reduce the immune response [114] . The structural differences in the length of PEG, fatty acids, and linker of the PEG-lipid conjugate used for modification of LNPs also strongly affect the potential of LNPs. LNPs modified with

blood retention but dramatically reduced gene-silencing effects in the liver [112, 113] . This is probably because the interaction between LNPs and cells is reduced or the ability of LNP to adsorb ApoE is reduced, resulting in difficulty in uptake into hepatocytes. The length of fatty acid chains of the PEG lipid is responsible for the time of dissociation from the LNPs. Since

PEGylated lipids with myristoyl (C14) chains are rapidly dissociated from the LNPs in the blood circulation, they do not interfere the process of FVII knockdown. We previously showed in mice that long circulation of siRNA-loaded pH-sensitive liposomes modified with PEG was observed only when DSPE-PEG but not distearoylglycerol (DSG)-PEG was used.

Our results suggest that the electrostatic interaction between lipid molecules on the surface of the liposomes is a critical determinant for the in vivo effect of PEGylation [116] .

PEGylation of LNPs and chemical modification of siRNA reduce their immunogenicity, but it is difficult to completely eliminate the possibility of immune reactions, especially in susceptible individuals [117] . siRNA was delivered to the target organs via systemic administration by attaching siRNA onto the particle (liposome) surface (lipoplex) [119, 120] . Since the accumulation of lipoplex in a tumor relies on the EPR effect [121, 122] , the surface of the lipoplex can be modified with a hydrophilic PEG polymer to increase its circulation time after intravenous injection;

otherwise, the lipoplex is rapidly captured by the reticuloendothelial system. On the other hand, it was reported that LNPs without a large amount of PEG modification are highly effective for liver targeting [28, 123, 124] . LNPs prepared with ionizable lipids form a protein corona in the bloodstream [125] . ApoE in the protein corona is recognized by receptors such as LDLR, which are overexpressed by hepatocytes [126] . Then, the complexes are internalized into hepatocytes via the ApoE-LDLR pathway [28, 123, 124] . siRNA in LNPs to prostate tumors in vivo by increasing the amount of PEG modification from 1% to 2.5 or 5%, resulting in inhibition of the growth of the implanted tumors [129] . We modified the LNP surface with HB-EGF antibody for the targeting of breast tumors [99, 104] .

HB-EGF is a ligand that binds to the EGF receptor (EGFR) [130] . It was reported that triple-negative breast cancer (TNBC; no estrogen receptor, progesterone receptor or human epidermal growth factor receptor2 [HER2]) [131] overexpresses HB-EGF [130] . The use of anti-HB-EGF antibody-modified LNP increased the amount of siRNA delivered into the breast tumor after the intravenous injection. It is known that TNBC is refractory and has high malignancy and poor prognosis. Several nano-materials such as functionalized mesoporous silica [132] , chitosan-layered gold particles [133] , and cationic lipid-based LNPs 

Despite the many efforts to improve siRNA delivery for cancer treatment [146] , an anticancer siRNA drug has not been launched yet. The anticancer effects of siRNA-based therapeutics may be still insufficient possibly due to delivery problems. Although LNP-mediated delivery of siRNA to liver tumors is promising because LNPs coated with ApoE in the blood are expected to be internalized into liver cancer cells via the ApoE-LDLR pathway, delivery systems of siRNA to other cancer tissues are still under exploration.

Identification and use of the internalization pathway selective for target cells will open the way to construct innovative LNP systems for cancer therapy. Because siRNA has great potential for cancer treatment, we strongly believe that the efforts in overcoming delivery problems contribute to the development of siRNA-based cancer therapy. Table 1 lists clinical trials in which lipid-based nanoparticles were used as a tool for siRNA delivery to cancers. EphA2-targeting DOPC-encapsulated siRNA (NCT01591356) is an siRNA-encapsulated liposome composed of DOPC. This candidate is expected to have a high therapeutic effect due to its excellent pharmacokinetics based on the high biocompatibility of neutral lipids [147] . The detailed lipid composition of the lipid-based nanoparticle called DCR-MYC (NCT02314052) has not been clarified, but the greatest feature is that the siRNA molecule encapsulated in DCR-MYC is designed to be efficiently cleaved by Dicer. Knockdown of the oncogene MYC was expected to be applicable for the J o u r n a l P r e -p r o o f treatment of various types of cancer, but its development is currently on hold as the results of a trial fell short of expectations [148] . TKM-080301 (NCT02191878) is a so-called SNALP containing DLin-DMA as a constituent lipid, and though well tolerated, its antitumor effect was limited [149] . It should be noted that trials using other ionizable lipids may be carried out in the future.

The rapid development of drug resistance and the harmful side effects of long-term siGag, si5'LTR, and siRev) was prepared and administered to SHIV SF162-infected rhesus monkeys intravaginally, leading to a significant drop in viral titer [167] .

HBV causes liver inflammation and is the cause of subsequent chronic infections.

Chronic HBV infection progresses to hepatic cirrhosis and then to liver cancer. Current anti-HBV therapy includes interferon (IFN)-α, PEGylated IFN, nucleoside analogue reverse J o u r n a l P r e -p r o o f transcriptase Inhibitors (lamivudine, adefovir, entecavir, terbivudine, and tenofovir) [168] .

Anti-HBV treatment is generally considered to cause drug resistance and has the risk of side effects such as liver failure [169] . Despite the development of many compatible drugs, it is difficult to completely eliminate HBV antigens such as Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) and covalently closed circular (ccc) DNA.

HBeAg) was successfully suppressed by siRNA-loaded YSK13-MEND in mice with persistently infected hepatitis B virus by silencing the sequences highly conserved among HBV strains [38] . In addition, GalNAc-modified PEG-coated LNP-siRNA reduced HBV replication in hepatocytes compared with that achieved with unmodified LNP [170] .

ARB-001467, which is an HBsAg-siRNA formulated in LNPs, has been shown to inhibit HBV protein production and to further reduce the cccDNA content in preclinical studies; and its phase 2 trial has been completed ( J o u r n a l P r e -p r o o f

HCV causes both acute and chronic hepatitis, killing approximately 400,000 people each year. Previously, "interferon treatment" using PEGylated IFN and ribavirin was used;

but recently, "interferon-free treatment" has become mainstream. "Interferon-free treatment"

is a treatment with direct-acting antiviral drugs including redipasvir, which can cure most HCV-infected individuals and shorten the treatment period. [171] .

In addition to virus-targeted therapy, siRNA-mediated knockdown of the viral replication mechanism in the host has been proposed. Lipidoid NPs containing siRNA targeting protein kinase C-related kinase 2 (PRK2), effectively inhibited HCV replication in a xenograft model and is attracting attention as a new HCV drug therapy [172] . Vitamin E-labeled cationic liposomes loaded with siRNA targeting HCV nonstructural protein 5A

was developed for hepatic delivery and shown to suppress both HCV core antigen production and HCV replication [173] .

Ebola virus disease (EVD) is an often deadly and contagious disease in primates,

causing Ebola hemorrhagic fever [174, 175] . siRNAs using lipid-based nanosystems (TKM-130803) have progressed to clinical trials, but unfortunately no significant protection J o u r n a l P r e -p r o o f has been achieved in infected patients [176] . However, it has been reported that the administration of LNPs containing siRNA to multiple targets (EK-1 mod, VP24, and VP35) to rhesus monkeys infected with lethal Zaire ebola virus (ZEBOV) improved the survival rate after infection [177] . [178] . A study in which an siRNA targeting Sudan Ebola virus VP35 was delivered by LNP also showed a prolonged survival of similarly infected non-human primates [179] .

Currently, coronavirus disease 2019 (COVID-19) is in a rage all over the world.

New therapeutic drug and vaccine candidates for COVID-19 are undergoing clinical trials.

Remdesivir was recently approved by the FDA for emergency use in patients with COVID-19. The viral genome that causes COVID-19 was reported to be closest to the severe acute respiratory syndrome (SARS) coronavirus group and was officially named SARS-CoV-2 [180] . It was recently revealed that SARS-CoV-2 utilizes angiotensin J o u r n a l P r e -p r o o f converting enzyme II (ACE2) as a receptor for intracellular entry [180] . With the progress of SARS-CoV-2 genome analysis, the sequences that can be targets of siRNA therapeutics have been identified [181] [182] [183] . Lipid-based nanoparticles are expected as a potential carrier useful for the development of siRNA therapeutics and mRNA vaccine for COVID-19.

LNPs targeting immune cells such as antigen-presenting cells are expected to be applicable for siRNA treatment of inflammatory and autoimmune diseases. The usefulness of LNPs containing various ionizable lipids (DLin derivatives) has been investigated for siRNA delivery to immune cells. LNP-mediated gene silencing of a target protein (GAPDH) on bone marrow-derived macrophages and dendritic cells was successful both in vitro and in vivo, and this system holds promise for the delivery of therapeutic siRNAs to treat various immune disorders [184] . Since delivery by the LNP system can deliver siRNA targeting CD45 to immune cells, it can be expected to be applied to neuroinflammation and autoimmune diseases related to Alzheimer's disease. Nakamura et al. showed that MEND composed of YSK12-C4, a second-generation ionizable lipid, induces remarkable gene silencing of target protein (GAPDH) on various human immune cell lines (Jurkat, THP-1, [185, 186] . In addition, they reported that J o u r n a l P r e -p r o o f some of the toxicological challenges of YSK12-C4 were overcome, with significantly reduced cytotoxic effects on natural killer cells (NK-92) and hemolytic activity [187] .

Controlling the function of T cells by RNAi is expected to be useful for the treatment of various diseases such as cancer and viral infections, and is therefore of great interest.

Ramishetti et al. reported that LNPs modified with anti-CD4 monoclonal antibodies efficiently delivered siRNA to CD4 + T lymphocytes in vitro and increased the accumulation of these cells in the spleen, lymph nodes, and bone marrow in vivo [103] . Furthermore, in recent years the expression of constitutive molecules (CD40, CD80, CD86) has been successfully knocked down by using LNP-siRNA to which an antibody against mouse DEC205+ dendritic cells had been bound [188] . Vitamin A-coupled lipid nanoparticles ( Table   2 , ND-L02-s0201), which inhibit the expression of collagen-specific chaperone HSP47, was clinically tested for the treatment of liver fibrosis; but it is currently used for the treatment of idiopathic pulmonary fibrosis (NCT03538301, Recruiting, Phase II).

Long-term gene silencing effects over 10 days can be obtained with systemic administration of siRNA-encapsulated LNPs [19] , suggesting that this system may be gain-of-function due to a missense mutation in the PCSK9 gene [193] . Standard treatment J o u r n a l P r e -p r o o f of ADH is statin treatment, but a significant proportion of patients do not reach their treatment goals even at the highest tolerated doses. In addition, because long-term administration of statins shows severe side effects, a new therapeutic approach has been awaited.

Lipidoid-NP loaded with PCSK9-siRNA (siPCSK9) was shown to reduce the LDL concentration in the blood for 3 weeks after intravenous administration in rodents and nonhuman primates [194] . Thereafter, a trial for LNPs encapsulating siPCSK9 for intravenous injection was clinically conducted ( Table 2 , NCT01437059) [195] . On the other hand, trials for the delivery of siPCSK9 conjugated with GalNAc for subcutaneous administration were conducted: a Phase I trial in 2014 (NCT02314442) and a Phase II one in 2016 (NCT02597127) and 2017 (NCT03060577). In the phase I trials, the knockdown effect remained for over 6 months, with safety [196] .

The most important risk factor for atherosclerosis is hyperlipidemia [197] . The development of atherosclerosis correlates with high levels of LDL. A high correlation between blood levels of apolipoprotein B (ApoB) and the risk of arteriosclerosis is known, but it is difficult to target ApoB with small molecule drugs. As such, siRNAs have been viewed as attractive treatment option, and an LNP-siRNA system consisting of DLin-DMA was previously reported to reduce plasma lipid levels [198] . A clinical trial of PRO-040201 J o u r n a l P r e -p r o o f using the SNALP system was started in 2010 but was terminated due to side effects on the immune system in high-dose patients ( Table 2 , NCT00927459) [199] .

Silencing of inflammatory cytokine genes including TNFα, NF-κB, and IL-1β is a promising approach for the treatment of rheumatoid arthritis. The delivery of TNF-siRNA by acid-sensitive sheddable PEGylated SLNs reduced collagen-induced inflammation in arthritis model mice that did not respond to methotrexate treatment [200] . It was also reported that NF-κB-siRNA and methotrexate encapsulated in folate-conjugated liposomes reduced the progression of arthritis and reduced inflammatory cytokines in a collagen-induced arthritis mouse model [201] . Lipidoid-polymer hybrid nanoparticles efficiently delivered siRNA targeting IL-1β to macrophages, resulting in effective suppression of pathologies such as paw swelling and bone destruction in experimental arthritis [202] .

BBB is a major obstacle for drug delivery to the brain. Unlike peripheral tissues, capillaries in the brain form a tight junction and have no fenestrae [203] . In addition, J o u r n a l P r e -p r o o f P-glycoprotein (P-gp), a kind of ATP-dependent drug transport protein, at the luminal side of endothelial cells selectively inhibits the accumulation of drug molecules in the brain [204] .

The development of a brain delivery system is thus required to overcome these hurdles.

Recent studies focused on brain delivery have offered a novel strategy for the treatment of neurological disorders. In addition to reducing drug size, delivering drugs to the brain via carrier-mediated transport involved in uptake such as that of glucose can be a very attractive strategy [205, 206] .

In 2013, it was reported that ionizable cationic lipid-LNP containing siRNA spread widely in the brain and showed significant knockdown of target mRNA (GRIN1, coding GluN1 subunit of NMDA [N-methyl-D-aspartate] receptor) in the brain after intracortical or intracerebroventricular injection without an immune response [207] . Conceicao, et al. Drugs that target cholinergic and glutamatergic neurotransmission have been developed for the treatment of cognitive impairment seen in Alzheimer's disease [209] . For J o u r n a l P r e -p r o o f instance, acetylcholinesterase inhibitors improve the symptoms of patients, but further drug development is required to address the unmet needs of Alzheimer's disease.

Chitosan-coated SLN modified with a CPP derived from RVG was shown to deliver siRNA into monolayer Caco-2 cells that mimics olfactory epithelium [210] . The results suggested that this SLN-siRNA may be a potential therapeutic candidate for Alzheimer's disease via the intranasal (nose-to-brain) delivery route. In another study to avoid the toxicity of cationic NPs, siRNA-anionic NP complexes were prepared by utilizing anionic PEG-liposomes and cationic targeting peptide [211] . Then, via intra brain injection of the complexes, the knockdown effect of siRNA against BACE1 (Beta-site amyloid precursor protein cleaving enzyme 1) was examined, with the result being a reduction in the number of amyloid plaques in the brain. Delivering siRNA with LNPs might be a useful approach for intractable neurodegenerative diseases by optimizing the formulation and injection route.

After the discovery of the RNAi phenomenon, numerous researchers thought that many intractable diseases might be cured by using synthetic siRNA; because siRNA is expected to be high specificity and low side effects. Although it is well known that the potential of siRNA is very promising for disease therapy, unfavorable siRNA properties such J o u r n a l P r e -p r o o f as easy degradation, low cellular uptake, and low endosomal escapability stand in the way of drug development. Up to now, a number of siRNA delivery carriers have been developed for the application of siRNA to intractable diseases. Finally, the first siRNA therapeutic was approved in 2018, i.e., Patisiran (ONPATTRO™). However, ONPATTRO™ is just the opening player of many future RNAi therapeutics. As highlighted in this review, many lipid-based nanoparticles have been developed for the improvement of siRNA properties, bioavailability, and pharmacokinetics. In addition, several siRNA-encapsulated LNPs show a therapeutic effect against cancer, inflammation, neurological disorder, and genetic disease.

The challenges faced regarding the above-mentioned unfavorable properties of siRNAs will be surmounted by the designing of high-performance LNPs. On the other hand, it is true that current strategies still lack in vivo efficiency and targeting ability (delivery to organs other than the liver). For future RNAi therapeutics, the discovery and development of LNP with innovative targeting functions that deliver therapeutic siRNA specifically into target cells are awaited. We strongly hope that attractive RNAi therapeutics for the treatment of intractable diseases will be developed shortly. 

RNA Targeting Therapeutics: Molecular Mechanisms of

Antisense Oligonucleotides as a Therapeutic Platform

Interfering with disease: A progress report on siRNA-based therapeutics

Role for a bidentate ribonuclease in the initiation step of RNA interference

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration

Rational design of cationic lipids for siRNA delivery

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Lipid-based systemic delivery of siRNA

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA

Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes

Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA

On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system

Octaarginine-modified multifunctional envelope-type nano device for siRNA

A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection

Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo

A Neutral envelope-type nanoparticle containing pH-responsive and ss-cleavable lipid-like material as a carrier for plasmid DNA

Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid J o u r n a l P r e -p r o o f Journal Pre-proof scaffolds

Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-Scaffold for nuclear targeting of plasmid DNA

A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma

Sinusoidal communication in liver fibrosis and regeneration

Hepatic stellate cell (vitamin A-storing cell) and its relative -past, present and future

The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Lipid-like materials for low-dose, in vivo gene silencing

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

Delivery materials for siRNA therapeutics

The size of endothelial fenestrae in human liver sinusoids: Implications for hepatocyte-directed gene transfer

Lipid nanoparticles silence tumor necrosis factor α to improve wound healing in diabetic mice

Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract

Lipospheres from microemulsions

Solid lipid nanoparticles (SLN) -An alternative colloidal carrier system for J o u r n a l P r e -p r o o f Journal Pre-proof controlled drug delivery

Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art

Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway

Solid lipid nanoparticles-A review

Review on Nanoparticles Used in Cosmetics and Dermal Products

Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA

Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo

Biodegradable nanoparticles with sustained release of functional siRNA in skin

In vivo sustained release of siRNA from solid lipid nanoparticles

Effect of the Ratio of Betamethasone to TNF-α siRNA Coencapsulated in Solid Lipid Nanoparticles on the Acute Proinflammatory Activity of the Nanoparticles

Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride

Extracellular vesicles: Biology and emerging therapeutic opportunities

Exosomes for drug delivery -A novel application for the mesenchymal stem cell

Mast cell-and dendritic cell-derived display a specific lipid composition and an unusual membrane organization

Cancer exosomes trigger fibroblast to myofibroblast differentiation

ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming

Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

ExoCarta: A Web-Based Compendium of Exosomal Cargo

Small RNA sorting: Matchmaking for argonautes

Effect of North Bicyclo[3.1.0]hexane 2'-Deoxy-pseudosugars on RNA Interference: A Novel Class of siRNA Modification

A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects

Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference

Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications

Exploring PAZ/3′-overhang interaction to improve siRNA specificity. A combined experimental and modeling study

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs

RNAi-mediated gene silencing

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

Ligand-targeted liposomal anticancer drugs

Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma

Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK

Quantitative measurements and rational materials design for intracellular delivery of oligonucleotides

Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation

Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement

Surface aggregation and membrane penetration by peptides: Relation to pore formation and fusion

Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA

Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs

Microfluidic self-assembly of folate-targeted monomolecular siRNA-lipid nanoparticles

Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells

Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling

Liposomal Nanomedicines: An Emerging Field

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures

Association of Blood Proteins with Large Unilamellar Liposomes in Vivo

Key determinants of siRNA delivery mediated by unique pH-responsive lipid-based liposomes

Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection

The niemann-pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA

Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles

Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA

Shielding of lipid nanoparticles for siRNA delivery: Impact on physicochemical properties, cytokine induction, and efficacy

Liposome clearance in mice: The effect of a separate and combined presence of surface charge and polymer coating

Design of a novel PEGylated liposomal vector for systemic delivery of siRNA to solid tumors

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids

Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin

Chapter 17 Engineering Cationic Liposome. siRNA Complexes for In Vitro and In Vivo Delivery

Exploring the tumor microenvironment with nanoparticles

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review

Effect of

DNA-encapsulating liposomal nanoparticles via intracerebroventricular administration

Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid

The role of apolipoprotein-And vitronectin-enriched protein corona on lipid nanoparticles for-And vivo targeted delivery and transfection of oligonucleotides in murine tumor models

Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins

Microfluidic hydrodynamic focusing synthesis of polymer-lipid nanoparticles for siRNA delivery

Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide

siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer

HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer

Molecular portraits of human breast tumours

Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles

Chitosan layered J o u r n a l P r e -p r o o f Journal Pre-proof gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer

Silencing β3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer

Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma

Mantle cell lymphoma: Evolving management strategies

Refining the mantle cell lymphoma paradigm: Impact of novel therapies on current practice

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma

Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

Expression of McI-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

Vascular normalization as an emerging strategy to enhance cancer immunotherapy

Advances in siRNA delivery in cancer therapy

Therapeutic EphA2 gene targeting in vivo using neutral interfering RNA delivery

Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

Nanotechnology and the treatment of HIV infection

Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment

Squalenoyl nucleoside monophosphate nanoassemblies: New prodrug strategy for the delivery of nucleotide analogues

Strategies in the design of nanoparticles for therapeutic applications

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years

HIV-protease inhibitors

Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome

Nanotechnology applications to HIV vaccines and microbicides

Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination

Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy

Nanotechnology: A magic bullet for HIV AIDS treatment

Recent trends on hydrogel based drug delivery systems for infectious diseases

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages

A multiple siRNA-based anti-HIV/SHIV Microbicide shows protection in both in vitro and in vivo models

Hepatitis B virus therapy: What's the future holding for us?

Lamivudine for patients with J o u r n a l P r e -p r o o f Journal Pre-proof chronic hepatitis B and advanced liver disease

Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

Nanostructures for the inhibition of viral infections

Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2

Target delivery of small interfering RNAs with Vitamin E-coupled nanoparticles for treating hepatitis C

Inactivation of Ebola virus with a surfactant nanoemulsion

Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome

Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

A new coronavirus associated with human respiratory disease in China

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells

Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells

Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core

Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses

Therapeutic siRNA silencing in inflammatory monocytes in mice

Targeting a monocyte subset to reduce inflammation

RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction

Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled

A highly durable RNAi therapeutic inhibitor of PCSK9

Understanding hyperlipidemia and atherosclerosis: Lessons from genetically modified apoe and ldlr mice

siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids

A status report on RNAi therapeutics

Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate

Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis

Lipidoid-siRNA Nanoparticle-Mediated IL-1β Gene Silencing for Systemic Arthritis Therapy in a Mouse Model

Solid lipid nanoparticles for targeted brain drug delivery

Advances in brain drug targeting and delivery: Limitations and challenges of solid lipid nanoparticles

Blood-brain barrier drug targeting: the future of brain drug development

Vector-mediated drug delivery to the brain

Lipid nanoparticle delivery of sirna to silence neuronal gene expression in the brain

Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype

Alzheimer's disease: clinical trials and drug development

Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy, Colloids Surfaces B Biointerfaces

Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery

The authors are grateful for the financial support by JSPS KAKENHI grant number 16K08201.